Chloe Kent
Reporter
Chloe is an award-winning journalist who has specialized in health reporting throughout her career, with a particular focus on women's health and access to medicine. Before joining Generics Bulletin she worked for B2B publishing consortium Verdict, writing about medical technology and pharmaceuticals. Having graduated from the University of York, she went on to train as a journalist with the Press Association.
Latest From Chloe Kent
Hyloris Lines Up Hectic Year Of Clinical Trials And Major US Launch
Hyloris has an eventful year ahead as it plans to conduct numerous trials for products in its ever-expanding pipeline and launch Maxigesic IV in the US.
Successful Cortrophin Gel Launch Could Drive Growth At ANI For Years To Come
The launch of ANI Pharmaceutical’s Cortrophin gel has reignited interest in the ACTH drug category, and appears set to drive growth at the company for the foreseeable future.
Pressure Builds For Biosimilars To Follow Lilly’s Lead After Insulin Price Cap
Biosimilar insulin producers are facing calls to improve patient affordability after Eli Lilly implemented a $35 price cap on copays for its insulins in the private market and for the uninsured.
FDA And FTC Continue To Collaborate On Biosimilar Competition
The FDA and FTC have been working on improving information exchange about activities which could undermine biosimilar competition, as well as addressing misinformation about factors such as interchangeability.
Generic Drugs Outlined As ‘Significant Public Health Priority’ For FDA
The FDA Office of Generic Drugs has published its annual report, highlighting its contributions to the approval of Viatris’ generic cyclosporine rival to Restasis, alongside updates to bioequivalence standards and support for competition.
Competitor Shortages Allow Amphastar To Deliver ‘Strongest Quarter Yet’
After shortages at competitor companies opened up gaps in the market Amphastar was able to step in to fill the void, leading to its most successful quarter yet with net revenues of $135m.